Chester County News and Community Website
BERWYN, PA — Chester County-based biopharmaceutical company Annovis Bio, Inc. (NYSE: ANVS) announced this week that its phase II/III study of buntanetap, a potential treatment for Alzheimer’s Disease (AD), has …
Annovis Bio’s Phase II/III Study of Buntanetap Exceeds Full Enrollment Read More
WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) this week announced disappointing top-line results from a Phase 2b study of zunsemetinib (ATI-450) in patients with moderate to severe rheumatoid arthritis …
Aclaris Therapeutics Halts Development of Rheumatoid Arthritis Drug After Phase 2b Study Misses Primary Endpoint Read More
MALVERN, PA — Biopharmaceutical company Ocugen, Inc. (NASDAQ: OCGN) has announced the commencement of its Phase 1/2 GARDian clinical trial for OCU410ST (AAV5-hRORA), a gene therapy candidate being developed to …
Ocugen Initiates Phase 1/2 GARDian Clinical Trial for Stargardt Disease Therapy Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN), a frontrunner in the world of biopharmaceuticals, recently disclosed its Q3 2023 financial results and a business update that holds promising news for …
Ocugen’s Promising Advancements: Q3 2023 Financial Results and Progress in Ophthalmic Gene Therapies, Regenerative Cell Therapies, and Vaccines Portfolio Read More
BERWYN, PA — Mural Health, a company specializing in patient-first clinical trial technology, is spearheading an initiative to improve access to experimental treatments for millions of Americans on public assistance. …
Mural Health Advocates for Income Exclusion to Boost Clinical Trial Diversity and Access Read More BERWYN, PA — In a recent breakthrough, Annovis Bio (NYSE: ANVS), a biopharmaceutical company, has successfully performed measurements of critical biomarkers in the plasma of Parkinson’s disease patients. Utilizing buntanetap, …
Annovis Bio’s Buntanetap Demonstrates Potential to Lower Key Biomarkers in Parkinson’s Disease Read More
BERYWN, PA — In a significant move that promises to reshape the future of pain management, Virpax Pharmaceuticals, Inc. (NASDAQ: VRPX) recently announced its intent to submit an Investigational New …
Virpax Pharmaceuticals’ Envelta Set for Human Trials Following FDA Review: A Potential Game-Changer in Pain Management Read More BERWYN, PA — Annovis Bio, Inc. (NYSE: ANVS), a biopharmaceutical company focused on developing novel treatments for neurodegenerative diseases, recently announced a significant milestone in its clinical trial journey. The …
Annovis Bio’s Buntanetap Trial for Alzheimer’s Disease Gets Green Light from DSMB: A Positive Step Forward Read More
According to recent data, Pennsylvanians have an optimistic outlook on their life expectancy. Residents predict they will live one year longer than the official state life expectancy which is good …
Pennsylvanians Are Optimistic About Their Life Expectancy Read More